Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Non-Current Liabilities (2019 - 2024)

Historic Total Non-Current Liabilities for Lipocine (LPCN) over the last 8 years, with Q3 2024 value amounting to $1.6 million.

  • Lipocine's Total Non-Current Liabilities fell 2961.34% to $1.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.6 million, marking a year-over-year decrease of 2961.34%. This contributed to the annual value of $2.6 million for FY2023, which is 5579.66% up from last year.
  • Latest data reveals that Lipocine reported Total Non-Current Liabilities of $1.6 million as of Q3 2024, which was down 2961.34% from $1.7 million recorded in Q2 2024.
  • Lipocine's Total Non-Current Liabilities' 5-year high stood at $6.1 million during Q4 2021, with a 5-year trough of -$42.4 million in Q1 2021.
  • For the 5-year period, Lipocine's Total Non-Current Liabilities averaged around -$12.0 million, with its median value being -$6.0 million (2020).
  • The largest annual percentage gain for Lipocine's Total Non-Current Liabilities in the last 5 years was 16111.26% (2021), contrasted with its biggest fall of 60436.77% (2021).
  • Lipocine's Total Non-Current Liabilities (Quarter) stood at -$10.0 million in 2020, then soared by 161.11% to $6.1 million in 2021, then tumbled by 72.56% to $1.7 million in 2022, then skyrocketed by 55.8% to $2.6 million in 2023, then crashed by 39.66% to $1.6 million in 2024.
  • Its Total Non-Current Liabilities was $1.6 million in Q3 2024, compared to $1.7 million in Q2 2024 and $1.4 million in Q1 2024.